Latest On ChromaDex Corporation (CDXC):
About ChromaDex Corporation (CDXC):
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
General
- Name ChromaDex Corporation
- Symbol CDXC
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 110
- Last Split Factor1:3
- Last Split Date2016-04-13
- Fiscal Year EndDecember
- IPO Date2008-07-15
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryLife Sciences Tools & Services
- Gic SubIndustryLife Sciences Tools & Services
- Web URLhttp://www.chromadex.com
Valuation
- Price/Sales (Trailing 12 Mt.) 12.03
- Price/Book (Most Recent Quarter) 38.43
- Enterprise Value Revenue 12.41
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.27
- Next Year EPS Estimate -$0.03
- Next Quarter EPS Estimate -$0.06
- Profit Margin -34%
- Operating Margin -34%
- Return on Assets -32%
- Return on Equity -108%
- Revenue 59.26 million
- Earnings Per Share -$0.60
- Revenue Per Share $0.97
- Gross Profit 35.27 million
- Quarterly Earnings Growth 18%
Highlights
- Market Capitalization 770.17 million
- EBITDA -31444000
- Analyst Target Price $16
- Book Value Per Share $0.27
Share Statistics
- Shares Outstanding 66.74 million
- Shares Float 46.59 million
- % Held by Insiders 3796%
- % Held by Institutions 25.12%
- Shares Short 2.16 million
- Shares Short Prior Month 2.01 million
- Short Ratio 0.3
- Short % of Float 4%
- Short % of Shares Outstanding 3%
Technicals
- Beta 1.81
- 52 Week High $16.82
- 52 Week Low $2.5
- 50 Day Moving Average 8.96
- 200 Day Moving Average 5.8
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
ChromaDex Corporation (CDXC) Dividend Calendar:
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
ChromaDex Corporation (CDXC) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-12-31 | 2021-03-10 | $N/A | -$0.11 | -$0.10 | -11.9% |
2020-09-30 | 2020-11-04 | $N/A | -$0.07 | -$0.09 | 22.22% |
2020-06-30 | 2020-08-06 | $N/A | -$0.06 | -$0.10 | 37.95% |
2020-03-31 | 2020-05-11 | $14.35 million | -$0.10 | -$0.11 | 6.98% |
2019-12-31 | 2020-03-10 | $13.09 million | -$0.11 | -$0.11 | 2.22% |
2019-09-30 | 2019-11-12 | $12.05 million | -$0.12 | -$0.12 | -4.35% |
2019-06-30 | 2019-08-07 | $11.1 million | -$0.14 | -$0.13 | -5.03% |
2019-03-31 | 2019-05-09 | $10.05 million | -$0.15 | -$0.12 | -28.53% |
2018-12-31 | 2019-03-07 | $9.07 million | -$0.15 | -$0.14 | -9.73% |
2018-09-30 | 2018-11-07 | $8.12 million | -$0.16 | -$0.13 | -28% |
2018-06-30 | 2018-08-09 | $7.8 million | -$0.15 | -$0.13 | -15.38% |
2018-03-31 | 2018-05-10 | $6.57 million | -$0.15 | -$0.06 | -150% |
2017-12-31 | 2018-03-08 | $7.53 million | -$0.17 | -$0.17 | 0% |
2017-09-30 | 2017-11-09 | $6.09 million | -$0.07 | -$0.05 | -40% |
2017-06-30 | 2017-08-10 | $4.22 million | -$0.05 | $0.04 | -219.75% |
2017-03-31 | 2017-05-11 | $3.37 million | -$0.05 | $0.01 | -600% |
2016-12-31 | 2017-03-16 | $4.45 million | -$0.06 | -$0.01 | -500% |
2016-09-30 | 2016-11-10 | $3.94 million | -$0.03 | ||
2016-06-30 | 2016-08-11 | $5.94 million | $-0.00 | ||
2016-03-31 | 2016-05-12 | $7.33 million | $0.01 | ||
2015-12-31 | 2016-03-17 | $4.36 million | -$0.04 | ||
2015-09-30 | 2015-11-12 | $6.29 million | $-0.00 | ||
2015-06-30 | 2015-08-13 | $6.1 million | -$0.01 | ||
2015-03-31 | 2015-05-14 | $5.26 million | -$0.03 | ||
2014-12-31 | 2015-03-19 | $4.24 million | -$0.04 | ||
2014-09-30 | 2014-11-06 | $4.14 million | -$0.02 | ||
2014-06-30 | 2014-08-12 | $3.86 million | -$0.05 | ||
2014-03-31 | 2014-05-08 | $3.07 million | -$0.06 | -$0.06 | 0% |
2013-12-31 | 2014-03-27 | $2.4 million | -$0.02 | -$0.06 | 66.33% |
2013-09-30 | 2013-11-22 | $2.72 million | -$0.04 | ||
2013-06-30 | 2013-08-13 | $2.71 million | -$0.03 | ||
2013-03-31 | 2013-05-10 | $2.34 million | $0.05 | ||
2012-12-31 | 2013-03-29 | $3.52 million | -$0.06 | -$0.12 | 50% |
2012-09-30 | 2012-11-08 | $3.63 million | -$0.06 | -$0.12 | 50% |
2012-06-30 | 2012-08-09 | $2.67 million | -$0.12 | ||
2012-03-31 | 2012-05-11 | $1.79 million | -$0.16 | ||
2011-12-31 | 2012-03-14 | $1.81 million | -$0.11 | ||
2011-09-30 | 2011-11-10 | $1.83 million | -$0.10 | ||
2011-06-30 | 2011-08-11 | $1.94 million | -$0.09 | ||
2011-03-31 | 2011-05-12 | $2.54 million | -$0.06 | ||
2010-12-31 | 2011-03-16 | $2.03 million | -$0.03 | ||
2010-09-30 | 2010-11-16 | $1.56 million | -$0.03 | ||
2010-06-30 | 2010-08-17 | $2.03 million | -$0.02 | ||
2010-03-31 | 2010-05-18 | $1.94 million | $0.00 | ||
2009-12-31 | 2009-12-31 | -$0.01 | |||
2009-09-30 | 2009-09-30 | -$0.02 | |||
2009-06-30 | 2009-06-30 | -$0.03 | |||
2009-03-31 | 2009-03-31 | -$0.03 | |||
2008-12-31 | 2008-12-31 | -$0.07 | |||
2008-09-30 | 2008-09-30 | -$0.07 | |||
2008-06-30 | 2008-06-30 | -$0.08 |
ChromaDex Corporation (CDXC) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
ChromaDex Corporation (CDXC) Chart:
ChromaDex Corporation (CDXC) News:
Below you will find a list of latest news for ChromaDex Corporation (CDXC) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
ChromaDex Corporation (CDXC) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|---|---|---|---|---|---|---|---|---|
2025-02-21 | 2.5 | 1.45 | CALL | 0 | 677 | 75.59 | TRUE | 0 | 0 |
2025-02-21 | 5 | 0.39 | CALL | 0 | 313 | 83.13 | FALSE | 0 | 0 |
2025-02-21 | 7.5 | 0.15 | CALL | 0 | 20 | 0 | FALSE | 0 | 0 |
2025-02-21 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
2025-02-21 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
2025-02-21 | 7.5 | 0 | PUT | 0 | 0 | 109.04 | TRUE | 0 | 0 |
2025-05-16 | 2.5 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
2025-05-16 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
2025-05-16 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
2025-05-16 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
2025-05-16 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
2025-05-16 | 7.5 | 0 | PUT | 0 | 0 | 76.06 | TRUE | 0 | 0 |
Latest CDXC Trades:
Date | Shares | Price |
---|---|---|
Jun 13, 2022 7:59 PM EST | 300 | $1.765 |
Jun 13, 2022 7:59 PM EST | 200 | $1.765 |
Jun 13, 2022 7:59 PM EST | 150 | $1.77 |
Jun 13, 2022 7:59 PM EST | 200 | $1.765 |
Jun 13, 2022 7:59 PM EST | 300 | $1.765 |
ChromaDex Corporation (CDXC) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-06-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1386570/000165495420007009/0001654954-20-007009-index.htm |
2020-05-28 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1386570/000000000020004753/0000000000-20-004753-index.htm |
2020-06-18 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1386570/000000000020005470/0000000000-20-005470-index.htm |
2020-05-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000089924320012130/0000899243-20-012130-index.htm |
2020-04-29 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1386570/000119312520125738/0001193125-20-125738-index.htm |
2020-05-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1386570/000119312520134908/0001193125-20-134908-index.htm |
2019-11-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588919001311/0001415889-19-001311-index.htm |
2020-02-14 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920000337/0001415889-20-000337-index.htm |
2020-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920000544/0001415889-20-000544-index.htm |
2020-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920000546/0001415889-20-000546-index.htm |
2020-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920000548/0001415889-20-000548-index.htm |
2020-02-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920000550/0001415889-20-000550-index.htm |
2020-03-31 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920000901/0001415889-20-000901-index.htm |
2020-05-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920001263/0001415889-20-001263-index.htm |
2020-05-20 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920001280/0001415889-20-001280-index.htm |
2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920001659/0001415889-20-001659-index.htm |
2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920001661/0001415889-20-001661-index.htm |
2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920001663/0001415889-20-001663-index.htm |
2020-06-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920001667/0001415889-20-001667-index.htm |
2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920001675/0001415889-20-001675-index.htm |
2020-06-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920001677/0001415889-20-001677-index.htm |
2020-11-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920002554/0001415889-20-002554-index.htm |
2020-11-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920002556/0001415889-20-002556-index.htm |
2020-11-06 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920002558/0001415889-20-002558-index.htm |
2020-11-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1386570/000141588920002560/0001415889-20-002560-index.htm |
2019-10-02 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1386570/000165495419011370/0001654954-19-011370-index.htm |
2019-10-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495419011618/0001654954-19-011618-index.htm |
2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1386570/000165495419012698/0001654954-19-012698-index.htm |
2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495419012705/0001654954-19-012705-index.htm |
2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495419012708/0001654954-19-012708-index.htm |
2020-01-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420000291/0001654954-20-000291-index.htm |
2020-03-10 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1386570/000165495420002437/0001654954-20-002437-index.htm |
2020-03-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420002438/0001654954-20-002438-index.htm |
2020-04-21 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1386570/000165495420004245/0001654954-20-004245-index.htm |
2020-04-21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1386570/000165495420004246/0001654954-20-004246-index.htm |
2020-04-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420004571/0001654954-20-004571-index.htm |
2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420005053/0001654954-20-005053-index.htm |
2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420005151/0001654954-20-005151-index.htm |
2020-05-12 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1386570/000165495420005192/0001654954-20-005192-index.htm |
2020-05-18 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1386570/000165495420005723/0001654954-20-005723-index.htm |
2020-05-18 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1386570/000165495420005725/0001654954-20-005725-index.htm |
2020-05-21 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1386570/000165495420005879/0001654954-20-005879-index.htm |
2020-05-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1386570/000165495420006038/0001654954-20-006038-index.htm |
2020-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420006116/0001654954-20-006116-index.htm |
2020-06-03 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1386570/000165495420006270/0001654954-20-006270-index.htm |
2020-06-12 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1386570/000165495420006554/0001654954-20-006554-index.htm |
2020-06-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420006880/0001654954-20-006880-index.htm |
2020-06-24 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1386570/000165495420006907/0001654954-20-006907-index.htm |
2020-06-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1386570/000165495420007009/0001654954-20-007009-index.htm |
2020-07-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420007469/0001654954-20-007469-index.htm |
2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420008588/0001654954-20-008588-index.htm |
2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1386570/000165495420008596/0001654954-20-008596-index.htm |
2020-08-18 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1386570/000165495420009302/0001654954-20-009302-index.htm |
2020-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1386570/000165495420011832/0001654954-20-011832-index.htm |
2020-11-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1386570/000165495420011840/0001654954-20-011840-index.htm |
2019-10-02 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1386570/999999999519002229/9999999995-19-002229-index.htm |
2020-06-01 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1386570/999999999520001306/9999999995-20-001306-index.htm |
2020-06-26 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1386570/999999999520001689/9999999995-20-001689-index.htm |
2019-10-24 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999719007343/9999999997-19-007343-index.htm |
2019-10-24 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999719007344/9999999997-19-007344-index.htm |
2020-03-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999720001256/9999999997-20-001256-index.htm |
2020-03-24 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999720001268/9999999997-20-001268-index.htm |
2020-03-24 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999720001269/9999999997-20-001269-index.htm |
2020-04-02 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999720001314/9999999997-20-001314-index.htm |
2020-05-26 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999720003131/9999999997-20-003131-index.htm |
2020-08-17 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999720004403/9999999997-20-004403-index.htm |
2020-09-11 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999720004631/9999999997-20-004631-index.htm |
2020-10-28 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1386570/999999999720005163/9999999997-20-005163-index.htm |
ChromaDex Corporation (CDXC) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of ChromaDex Corporation (CDXC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 3796%Institutional Ownership: 2512%
Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
---|---|---|---|---|---|---|---|---|
2020-05-19 | Robert N Fried | CEO | Buy | 1,000.00 | 4.69 | 4,690.00 | 1,393,314.00 | https://www.sec.gov/Archives/edgar/data/1386570/000141588920001263/0001415889-20-001263-index.htm |
2019-11-14 | Robert N Fried | CEO | Buy | 10,000.00 | 3.09 | 30,900.00 | 1,444,315.00 | https://www.sec.gov/Archives/edgar/data/1386570/000141588919001311/0001415889-19-001311-index.htm |
2020-11-06 | KEVIN M FARR | CHIEF FINANCIAL OFFICER | Buy | 5,000.00 | 4.43 | 22,150.00 | 41,625.00 | https://www.sec.gov/Archives/edgar/data/1386570/000141588920002560/0001415889-20-002560-index.htm |